Price Data
| Stock |
Price |
1D |
7D |
30D |
3M |
52wkHi |
RSI |
Status |
Action |
| TMO |
$510.93 |
-0.8% |
-3.1% |
-19.7% |
-13.0% |
-20.1% |
19↓ |
🔴 Extreme Oversold |
✅ Buy |
Price vs Last Deep Dive (02/16)
| Metric |
02/16 |
02/22 |
Change |
| Price |
$504.82 |
$510.93 |
+$6.11 (+1.2%) |
| RSI |
5.5 |
19.2 |
+13.7 (dramatic improvement) |
| SMA20 |
$579.97 |
$556.36 |
-$23.61 (SMA declining toward price) |
| vs SMA |
-13.0% |
-8.2% |
Gap narrowing |
Update from 02/16: The most dramatic RSI recovery in our coverage — from extreme RSI 5.5 to 19.2 (+13.7 points) while price only moved +1.2%. This is the RSI oscillator catching up to the price stabilization. The SMA has declined from $580 to $556, further narrowing the gap. Still in deep oversold territory (RSI 19) but clearly past the most extreme phase. Insider selling ($323.3M) remains the key risk overhang alongside IQV. The life sciences picks-and-shovels thesis is unchanged.
Company Overview
One-Liner
Thermo Fisher Scientific is the world's largest life sciences company, providing analytical instruments, equipment, reagents, and services to every lab and pharma company globally.
Business Model
| Question |
Answer |
| What they sell |
Lab instruments/equipment, scientific reagents, specialty chemicals, CRO/bioprocessing services |
| Who pays |
Pharma/biotech (50%), hospitals/diagnostic labs (20%), academic/government (20%), industrial (10%) |
| Revenue model |
Equipment sales (one-time), consumables/reagents (recurring), service contracts, bioproduction (recurring) |
| How sticky |
Very high — scientific instruments require calibration, reagents are qualified per protocol, switching risks experiment reproducibility |
Key Segments
| Segment |
Revenue % |
Growth |
Notes |
| Life Sciences Solutions |
~35% |
+8% YoY |
Reagents, bioprocessing, gene editing tools |
| Analytical Instruments |
~25% |
+6% YoY |
Mass spec, chromatography, electron microscopy |
| Specialty Diagnostics |
~20% |
+5% YoY |
Clinical diagnostic kits, allergy testing |
| Laboratory Products & Biopharma Services |
~20% |
+4% YoY |
Lab supplies, CRO services (PPD) |
Competitive Analysis
Competitive Moat
| Moat Type |
Present? |
Evidence |
| Switching costs |
🟢 |
Scientific protocols lock in specific instruments/reagents; revalidation cost is prohibitive |
| Intangible assets |
🟢 |
Thermo, Fisher Scientific, Life Technologies brand trust in research community |
| Network effects |
🟡 |
Scientific literature references specific TMO instruments/reagents |
| Cost advantages |
🟢 |
$45B+ revenue generates unmatched supply chain scale |
| Efficient scale |
🟢 |
Only company covering full lab workflow from sample prep to analysis |
Moat Width: Wide
Moat Trend: Stable — life sciences R&D spend is structural, not cyclical long-term
TMO vs IQV (Comparison)
Both are life sciences compounders now at extreme oversold:
| Metric |
TMO |
IQV |
| RSI |
19.2 |
25.5 |
| 30D |
-19.7% |
-31.4% |
| Moat |
Wide |
Wide |
| Revenue |
$45B |
$16B |
| Insider Selling |
$323.3M |
-$39.8M |
| Recovery Signal |
RSI +13.7 pts |
RSI +11.5 pts |
Bull Case
Why This Could Work
- Essential life sciences infrastructure — Every hospital, pharma company, and lab needs TMO products. No substitution.
- Bioproduction secular tailwind — mRNA, cell therapy, gene editing all require TMO's bioprocessing equipment.
- RSI recovery from 5.5 to 19.2 — Most dramatic RSI improvement in coverage. Worst selling is over.
- Picks-and-shovels for pharma AI — AI drug discovery increases demand for analytical instruments.
- SMA declining toward price — Technical convergence accelerating.
Upside Scenario
| If This Happens |
Stock Could |
| Bioproduction recovery + multiple normalization |
$650 (+27%) |
| Pharma R&D spending re-acceleration |
$700 (+37%) |
Bear Case
What Could Go Wrong
- Pharma R&D budget cuts — Largest customer segment cutting spending post-COVID boom.
- Insider selling $323.3M — Among highest in our universe alongside ISRG.
- China exposure — ~15% China revenue; geopolitical risk on analytical instruments.
- CRO competition — PPD segment (acquired 2021) faces IQVIA competition.
Thesis Killers
- Pharma top 10 companies announce R&D budget cuts exceeding 10%
- China bans TMO instrument imports
- Bioproduction demand collapses (mRNA era over)
Entry Strategy
Technical Levels
| Level |
Price |
Notes |
| Support 1 |
$490 |
Recent floor / entry zone bottom |
| Support 2 |
$440 |
Stop-loss; multi-year support |
| Resistance 1 |
$556.36 |
SMA20 |
| Resistance 2 |
$600 |
3-month prior range |
| 52-week high |
$639.45 |
Jul 2025 |
| 52-week low |
~$460 |
(estimated) |
Entry Approach
| Strategy |
Details |
| Entry zone |
$490 - $525 |
| Starter |
2% of portfolio |
| Add |
RSI breaks above 25 with price above $520 |
| Full |
RSI > 30 + SMA20 convergence |
Research Log
| Date |
Update |
| 2026-02-16 |
Created deep dive. RSI 5.5 extreme (!). $504.82. -13% below SMA. Insider selling $323.3M. Action: Buy. |
| 2026-02-22 |
Price refresh. $510.93 (+1.2%). RSI 19.2 (from 5.5 — largest improvement in coverage: +13.7 pts). SMA gap narrowed from -13% to -8.2%. Still extreme oversold. Buy maintained. |
The Gold
Key Discoveries
| Discovery |
Implication |
| RSI 5.5 → 19.2 (+13.7 pts) = largest improvement in coverage |
TMO's capitulation phase has ended; recovery beginning |
| Price only +1.2% while RSI +13.7 |
RSI was extremely depressed; now normalizing |
| SMA gap narrowing from -13% to -8.2% |
Convergence accelerating |
| Insider selling $323.3M concern |
Tempers position size vs pure RSI signal |
Open Questions
- What drove the RSI 5.5 extreme — was it forced selling/index rebalancing?
- Are the insider sales ($323.3M) on scheduled 10b5-1 plans?
- What is TMO's China revenue exposure and risk?
- When does TMO report next earnings?
Mistakes (Don't Repeat)
| Mistake |
Lesson |
| None yet |
RSI 5.5 → 19 recovery pattern = buy the bounce confirmation |
Sources
- Fundamentals figures: company-reported results (quarterly/annual filings) as available at the artifact date; predates the desk's EDGAR reconciliation gate — figures not re-verified after publication.